Bacterial Etiology of Urinary Tract Infections In Kenyan Health Facilities And resistance towards commonly used antibiotics

Author;

Susan Kiiru[1], John Maina[1], Japhet Katana[1], John Mwaniki[1], John Kiiru[1,2]

[1] *Centre for Microbiology Research, Kenya Medical Research Institute, P.O. Box 19464, 00202, Nairobi, Kenya.*

[2]. *National Public Health Laboratories, Ministry of Health, Kenya.*

Corresponding author; suzikoah@gmail.com, SKiiru@kemri.go.ke

1.0 Abstract

Background

Evidence-based empirical antibiotic prescribing requires knowledge of local antimicrobial resistance patterns. This study investigated the prevalence of UTI causative bacteria and their corresponding antibiotic resistance profiles in three counties to determine the best empirical therapies for UTIs management.

Objective

The main aim of the present study was to determine the prevalence of UTIs among patients seeking treatment in selected healthcare facilities in Kenya and the antibiotic resistance profile of the etiologic agents.

Methods

In this mixed methods study, urine samples were collected from patients who presented with UTI-like symptoms in the following healthcare facilities; KNH, Kiambu hospital, Mbagathi, Makueni, Nanyuki, Centre for Microbiology Research, and Mukuru health centers. Urine cultures were done on CLED to isolate UTI bacterial etiologies, while antibiotic sensitivity testing was done using the disk diffusion and their antibiotic susceptibilities Kirky Bauer technique

Results

A total of 1,027(54%) uropathogens were isolated from urine samples of 1898 respondants. *Staphylococcus* spps and *E. coli* were the main uropathogens at 34.2% and 26.1 %, respectively. Average resistance profiles for commonly used drugs for the treatment of UTI were as follows; Trimethoprim (64%), Sulfamethoxazole (57%), Nalidixic Acid(54%), Ciprofloxacin (26%), Cefuroxime (13%), Amoxicillin-clavulanic acid (10%), Nitrofurantoin (9%), Cefixime (7%). Resistance to broad-spectrum antimicrobials, such as Ceftazidime, Gentamicin, and Ceftriaxone, was at 15%, 14%, and 11%, respectively. Additionally, the proportion of Multidrug-resistant(MDR) bacteria was 66%.

Conclusion

High resistance rates towards Floro/quinolones, Sulfamethoxazole, and Trimethoprim were reported, which are the commonly used drugs as they are cheap to buy and readily available. Based on these findings, there is need for adapted UTIs antibiotic treatment threapy, informed by routine surveillance.

Keywords; Uropathogens, UTI, antibiotic resistance.

1.1 Background

Urinary tract infections (UTIs) are among the community's most common infections [1] accounting for nearly 25% of all common infections. Globally, UTI is more common among the aged, prepartum neonates, pregnant women, and hospitalized patients, especially those in Intensive Care Unit(ICU) and those with indwelling catheters. Usually, community-acquired UTIs are more prevalent than hospital-acquired UTIs. Even though UTIs are easily treated using antibiotics, widespread antibiotics usage without proper susceptibility testing has inevitably led to increased UTI pathogens resistant to affordable and available antibiotics. Understanding local antimicrobial resistance patterns is a baseline step for evidence-based empirical antibiotic prescribing[2]. Continuous surveillance and monitoring of AMR trends are vital to informing clinical decisions during empirical management of UTIs in health facilities lacking laboratory capacity to perform culture and sensitivity tests. In order to administer an appropriate empirical therapy, it is critical to know the main uropathogens and their corresponding antimicrobial susceptibility pattern [3].

The most susceptible cohort to Community-acquired urinary tract infections (UTIs) is women [4] . It is estimated that ~50% of women will have at least one UTI episode in their lifetime, while 20 - 40% will have recurrent episodes [5]. Pregnant women are more susceptible to UTIs due to hormonal and physiologic changes predisposing them to bacteriuria [6]. Up to 70% of women during pregnancy develop glycosuria, which encourages bacterial growth in the urine [7]. Antibiotic therapy for these infections usually begins before microbiological test results are known. Furthermore, empirical therapy without a pretherapy urine culture is often used in women with acute uncomplicated cystitis. The rationale for this approach is based on the highly predictable spectrum of etiologic agents causing UTIs and their antimicrobial resistance patterns. However, antimicrobial resistance among uropathogens causing complicated and uncomplicated community-acquired UTIs is gradually

71 increasing. Most significant has been the increasing resistance to Trimethoprim-
72 Sulfamethoxazole(SXT), commonly sold as Septrin, the current drug of choice for treating
73 acute uncomplicated cystitis in women [8]. In addition, Trimethoprim-
74 Sulfamethoxazole(SXT) is frequently associated with concurrent resistance to other
75 antibiotics classes, resulting in multidrug-resistant uropathogens [8].
76 In Kenya, the most common Gram-negative etiologic agents (in order of prevalence)
77 encountered in UTI cases are *E. coli, Klebsiella, Enterococcus, Enterobacter*, and *Proteus.* At
78 the same time, *Staphylococcus* is the most common Gram-positive species [9]. Determining
79 microorganisms and their antibiotic sensitivity patterns allows for good treatment outcomes,
80 controls the increase of antimicrobial prescription, and helps prevent antimicrobial resistance,
81 a public health problem worldwide. This paper establishes the common uropathogens from
82 different healthcare facilities across Kenya and their corresponding susceptibility patterns.

83 **2.0 Methodology**

84 **2.1 Study Overview**

85 Finding reported in present manuscript are a subset of a large HATUA (Holistic Approach
86 Towards Unraveling Antibiotic resistance in East Africa study. This East African consortium
87 included Kenya, Uganda, and Tanzania. The study employed social science, Micro- and
88 Molecular biology disciplines to unravel drivers of AMR holistically using UTI as the flag
89 disease. In Kenya's chapter, the study was conducted in Nairobi, Makueni, and Nanyuki
90 metropolis regions.

91 **2.2 Study design and site**

92 A cross-sectional study design was employed to establish the common uropathogens
93 recovered from purposively recruited 1898 patients with UTI-like symptoms and their
94 corresponding antibiotics susceptibility patterns. The participants were recruited from
95 selected hospitals in Nairobi, Nanyuki, and Makueni counties, including; Kenyatta National

Hospital, Mbagathi County Hospital, Kiambu County Hospital, Mary Mother Mission Mukuru healthcare, Ruiru Family Clinic, KEMRI Centre for Microbiology Research Lab, Nanyuki Teaching and Referral Hospital, and Makueni Level 5 Hospital.

2.3 Recruitment and laboratory procedures

2.3.1 Recruitment

A medical doctor (resident in the hospital selected for study)identified patients for recruitment based on the standard procedure for diagnosing UTIs and referred these patients to a study recruiting healthcare worker who was in a separate room within the hospital. The researcher introduced the patient to the study and briefly explained the study objectives. Willing patients were then taken through the study informed consent document (ICD) in a language they could understand (English and/or Kiswahili). Those who consented were given a study number that was filled in their questionnaire form. This study number was also written on the sample collection container. After consenting, the participant was requested to submit the urine samples. For inpatients with UTI-like symptoms, the attending nurse identified them and recruited them.

2.3.2 Urine collection procedure

Clean-catch mid-stream urine was collected into 20 mL calibrated sterile screw-capped universal bottles. The adult participants were guided on how to collect the specimen by the fieldworker(s) aseptically. The fieldworker also assisted parents in collecting urine specimens from their children (from ages that cannot easily give a urine sample). The specimens were labeled, transported to the microbiology laboratory, and analyzed within 4 hrs. A unique study identification number and/or bar code label was applied to the sample immediately after urine collection.

2.3.3 Bacterial isolation and identification

120 Urine samples were analyzed using dipstick strips, and CFU was determined by culture as the
121 gold standard. The patients were first screened by dipstick analysis, using nitrates and
122 leukocyte esterase parameters to rule out positive and negative test. Both positive and negative
123 urine by dipstick were then cultured on Cystine Lactose Electrolyte Deficient (CLED) agar and
124 incubated at 37 ℃ overnight. Culturing both negative and positive urine was to detect possible
125 UTI cases that may have been missed by dipstick test screening. A specimen was considered
126 positive for Urinary Tract Infection (UTI) if an organism was cultured at a concentration of
127 $\geq 10^5$CFU/mL or when an organism was cultured at a concentration of 10^4CFU/mL and >5 pus
128 cells per high-power field observed on microscopic examination of the urine as described by
129 [10]. Additionally, bacterial identification was made using colony morphology, Gram staining,
130 and conventional biochemical tests.

131 **2.3.4 Antimicrobial Susceptibility testing**

132 Antimicrobial drug susceptibility testing was done using the Kirby Bauer disk diffusion
133 method on Mueller–Hinton agar following the CLSI 2019 guidelines. The following Oxoid™
134 antimicrobial agents were used; ampicillin (AMP 10µg), amoxicillin/clavulanic acid (AMC
135 20/10µg), cefoxitin (FOX 30µg), cefotaxime (CTX 30µg), ceftazidime (CAZ 30µg),
136 cefuroxime (CXM 30µg), ceftriaxone (CRO 30µg), Cefepime (FEP 30µg), Ciprofloxacin
137 (CIP 5µg), Nalidixic Acid (NA 30µg), Nitrofurantoin (NIT 300µg), trimethoprim-
138 sulfamethoxazole (SXT 1.25/23.57µg), gentamicin (C.N. 10µg), chloramphenicol (C 30µg),
139 tetracycline (TET 30µg), Linezolid(LZD 30µg), Erythromycin(E 30µg), Vancomycin(VA
140 30µg), Fosfomycin(FOS 30µg), Amikacin (AK 30µg), Aztreonum (ATM 30µg), Fusidic Acid
141 (F.D. 30µg), and Streptomycin (S 30µg). For each Gram-negative isolate, two plates with
142 antibiotics were used, labeled as plate A and B. Plate A targeted Extended Spectrum Beta
143 Lactamases (ESBL) production. The arrangement of antibiotics was as follows, penicillins
144 (AMP), 3rd generation cephalosporin (CRO, CAZ, CTX), Cephamycin (FOX), monobactam

(ATM), inhibitor at the middle (AMC), and a 4th generation cephalosporin (FEP). In plate B, CIP, NA (targeting quinolones and fluoroquinolones resistance), C.N., AK, and S(targeting aminoglycosides resistances), C, SXT, F, and TET were used since they are used in hospitals for treatments. Moreover, Gram-positive isolates had three plates labeled plates A, B, and C. Plate A and B had the same drugs as those in Gram-negative plates, while plate C had Linezolid, Erythromycin, Vancomycin, Fosfomycin, and Fusidic Acid. *Escherichia coli* ATCC 25922 and *staphylococcus aureus* ATCC 25923 were used for quality control of media quality and disc potency. The antibiograms generated were then used to cluster the isolates into various resistance profiles ranging from fully sensitive to resistances to multidrug-resistant. The strains exhibiting resistance to 3 or more classes of antibiotics were scored as MDR[11].

2.4 Ethical Statement

Before the start of the study, ethical approval was obtained from the Scientific Ethical Review Committee (SERU) of Kenya Medical Research Institute (No.KEMRI/SERU/CMR/P00112/3865). Additional ethical approval was obtained from National Commission for Science, Technology and Innovation (NACOSTI), and the study recruitment healthcare facilities. Consent was sought before recruiting the participants for the study, and the names of the participants were not taken.

3.0 Results

3.1 Socio-demographic Characteristics and Prevalence of UTI.

One thousand eight hundred ninety-eight patients who presented with UTI-like symptoms were recruited between May 2019 and August 2020. Among them, 1546 (81.5%) were females, while 352 (18.5%) were males. A total of 67 (3.5%) were children, and 1831 (96.5%) were adults. Of the adults, 1707 (93.2%) were outpatients, while 124 (6.8%) were inpatients. Twenty-two (32.8%) of the children were inpatients, while 45 (67.2%) were outpatients, as illustrated by **Table 3.1** below. The average age of the study participants was 30.66 ± 12.138 years, with the youngest being one year old and the oldest 102 years. In addition, 1277 (67.3%) participants had prior knowledge of UTI, while 621 (32.7%) were not aware of UTI.

The overall UTI prevalence was 1027(54.1 %), with women having a higher prevalence of 917 (59.3%) compared to men at 110(31.3%). UTI was highest in the age-group 25-30 years at 16.2% and the lowest (1.2%) in children under five years. In addition, UTI prevalence was profound in Nanyuki Teaching and Referral Hospital at 17.7% and least in Ruiru Family Clinic at 0.4 %, **Fig 3.1**. The difference in UTI prevalence across the eight study sites was significantly different at P > 0.000.

Fig 3.1 UTI prevalence across recruitment sites.

Table 3.1 Demographic characteristics of the study participants

Social demographic characteristics		Female N (%) (n = 1546)	Male N (%) (n = 352)	Total (n = 1898)
Patient type	Adult inpatient	81 (65.3)	43 (34.7)	124 (100)
	Adult outpatient	1429 (83.7)	278 (16.3)	1707 (100)
	Child inpatient	9 (40.9)	13 (61.9)	22 (100)
	Child outpatient	28 (62.2)	17 (37.8)	45 (100)
Recruitment site	CMR	17 (58.6)	12 (41.4)	29 (100)
	Kenya Ruiru Family clinic(KRF)	22 (81.5)	5 (18.5)	27 (100)
	KIAMBU	182 (78.4)	50 (21.6)	232 (100)
	KNH	84 (67.2)	41 (32.8)	125 (100)
	MAKUENI	354 (92.7)	28 (7.3)	382 (100)
	MBAGATHI	112 (73.7)	40 (26.3)	152 (100)
	MMM	320 (82.7)	67 (17.3)	387 (100)
	NANYUKI	413 (85.5)	70 (14.5)	483 (100)
Study Location	Central Kenya (Nanyuki)	414 (85.4)	71 (14.6)	485 (100)
	Larger Nairobi Metropolis	778 (75.5)	253 (24.5)	1031 (100)
	MAKUENI	354 (92.9)	27 (7.1)	381 (100)
Age group	< 5 years	10 (33.3)	20 (66.7)	30 (100)
	6-18 years	66 (81.5)	15 (18.5)	81 (100)
	19-24 years	425 (92.6)	34 (7.4)	459 (100)
	25-30 years	497 (84.5)	91 (15.5)	588 (100)
	31-35 years	249 (83.3)	50 (16.7)	299 (100)
	35-40 years	142 (78.5)	39 (21.5)	181 (100)
	41-45 years	60 (69.0)	27 (31.0)	87 (100)
	46-50 years	27 (60.0)	18 (40.0)	45 (100)
	51-55 years	21 (65.6)	11 (34.4)	32 (100)
	56-60 years	14 (53.8)	12 (46.2)	26 (100)
	> 60 years	35 (50.7)	34 (49.3)	69 (100)
UTI knowledge	No	432 (70.1)	189 (30.6)	621 (100)
	Yes	1114 (87.2)	163 (12.8)	1277 (100)
culture significance	Positive	917(89.3)	110(10.7)	1027(54.1)
	Negative	629(72.2)	242(27.8)	871(45.9)

3.2 Bacterial isolates

188 Of all (1027/1898) UTI-positive patients *Staphylococcus* spps and *E. coli* were
189 the main uropathogens isolated at 34.2% and 26.1%, respectively. Other uropathogens
190 included *Enterococcus* spp (9.9%), *Klebsiella* spp (9.4%), *Proteus* spp (7.8%),
191 *Pseudomonas*(0.7%), *Serratia*(0.7%), *Streptococcus*(0.3%), *Acinetobacter*(1.3%), *Bacillus*(
192 1.8%), Yeast(1 %). A total of 70 (6.8%) organisms were not identifiable using the I.D.
193 scheme applied in this study **fig 3.2**. Gram-positive uropathogens were more prevalent at 524
194 (51%), followed by gram negatives at 490 (48%) and Yeast at 10 (1%.)

195

196 **Key; ND- non-identified, E.coli- *Escherichia coli***

197 **Fig 3.2: %** Proportion of Uropathogens recovered from 1027 positive cultures.

198 **3.3 Antimicrobial Susceptibility Testing**

199 The recovered uropathogens were subjected to antibiotic susceptibility testing. However,
200 Yeast isolates were not tested, resulting in 1016 bacterial isolates for ASTs. Overall, the
201 average resistance profiles to commonly used UTI drugs were as follows; Trimethoprim
202 (64%), Sulfamethoxazole (57%), Nalidixic Acid(57%), Ciprofloxacin (27%), Cefuroxime
203 (9%), Nitrofurantoin (9%), Cefixime (9%) and Amoxicillin-clavulanic acid (5%). Resistance
204 to broad-spectrum antimicrobials, such as Gentamicin, Ceftriaxone, and Ceftazidime, was at
205 14%, 9%, and 8%, respectively. Cefixime, Nitrofurantoin, and Amoxicillin Clavulanic Acid
206 were the most effective agents against these isolates, while Trimethoprim, Sulfamethoxazole,
207 and Nalidixic Acid were the most resisted antibiotics, **Fig 3.3**. *Staphylococcus* spps, the
208 dominant uropathogen, showed the highest resistance towards Trimethoprim(76%),
209 Nalidixic acid (70%), Sulfamethoxazole(67%), and Ampicillin(64%). Similarly resistance
210 towards cefoxitin was 38%, signifying the possiblilty of MRSA. Moreover, all isolated
211 *Pseudomonas* spps (8) showed 100% resistance towards cefuroxime as well as high

212 resistance towards ciprofloxacin (39%), Nalidixic Acid (50%), Nitrofuratoin (38%),
213 Sulfamethoxazole (38%) and Trimethoprim(38%) . The proportion of Multidrug-resistant
214 (MDR) pathogens was 66%, with the most common MDR phenotype observed being a
215 combination of Nalidixic Acid, Sulfamethoxazole, and Trimethoprim**.** The resistance towards
216 Nalidixic Acid was high across all the recruitment sites, ranging from 52 to 71%, as **Table**
217 **3.3** depicts. The resistance towards the mainstay treatments of UTI, betalactams, Quinolones,
218 Fluoroquinolones, and Aminoglycosides, commonly abbreviated as BFQA, was high in
219 Kenyatta National Hospital, ranging from 31 to 43% and was lowest at Ruiru Family Clinic
220 ranging from 0 to 13%, as well shown in the highlighted part of **Table 3.3.**

221 **Fig 3.3 antibiotics resistance profiles (%) of all the uropathogens recovered:** AMC-
222 Amoxicillin Clavulanic acid, AMP- Ampicillin, CXM-Cefixime, CAZ-Ceftazidime, CRO-Ceftriaxone, CTX-
223 Cefotaxime, FOX-Cefoxitin, CFM-Cefepime, ATM-Aztreonam, AMK-Amkacin, GEN-Gentamicin, RIF-
224 Rifampicin, NAL-Nalidixic Acid, CIP-Ciprofloxacin, SMX-Sulfamethoxazole, TMP-Trimethoprim, FOS-
225 Fosfomycin, NIT-Nitrofurantoin, LNZ-Linezolid, VAN-Vancomycin, CHL-Chloramphenicol, TCY-
226 Tetracycline, FUS-Fusidic Acid. Numbers in brackets are the n.

Table 3.3: Antibiotic Resistance % across all recruitment sites.

	% Resistance per recruitment site																					
Study Site	AMP	AMC	CFM	CAZ	CRO	CTX	FOX	CFM	ATM	AK	CN	R.D.	NA	CIP	RL	W	FOS	F	LZD	VA	C	TET
CMR	41	18	0	18	18	24	18	18	33	0	24	0	71	29	41	47	0	6	0	0	12	29
Kenyatta National Hospital	39	32	41	37	36	37	43	31	63	43	37	44	71	37	61	64	3	19	34	11	20	47
Kiambu County hospital	23	21	37	20	21	21	25	19	50	10	17	38	61	22	51	56	0	12	33	5	10	30
Makueni Level 5	39	13	15	15	17	18	17	14	47	10	11	21	55	20	51	69	0	6	19	3	10	43
Mbagathi hospital	26	26	33	18	21	26	24	18	53	13	16	20	58	21	44	68	7	16	33	0	12	35
Nanyuki county referral	37	19	18	20	23	24	17	16	42	10	11	29	52	26	59	69	3	9	26	13	9	39
Ruiru family clinic	25	13	0	13	13	13	13	13	50	0	13	0	63	13	38	38	0	13	0	0	13	13
MMM	48	21	0	21	21	23	24	20	41	4	13	13	59	14	71	57	0	10	15	1	7	38

Key; AMC- Amoxicillin Clavulanic acid, AMP- Ampicillin, CXM-Cefixime, CAZ-Ceftazidime, CRO-Ceftriaxone, CTX-Cefotaxime, FOX-Cefoxitin, CFM-Cefepime, ATM-Aztreonam, AMK-Amkacin, GEN-Gentamicin, RIF-Rifampicin, NAL-Nalidixic Acid, CIP-Ciprofloxacin, SMX-Sulfamethoxazole, TMP-Trimethoprim, FOS-Fosfomycin, NIT-Nitrofurantoin, LNZ-Linezolid, VAN-Vancomycin, CHL-Chloramphenicol, TCY-Tetracycline, FUS-Fusidic Acid, MMM-Mary Mother Mission Mukuru hospital, CMR-Centre for Microbiology Research. The dotted line shows the NAL resistance across all recruitment sites.

Discussion

Often, community urinary tract infections are uncomplicated and easily manageable with readily available antibiotics. However, over-the-counter prescription and empirical treatment have resulted in the emergence of strains that no longer respond to readily available antimicrobials, leading to treatment failure and cycles of recurrent UTI infections. Notably, the community's acquired UTI burden varies across geographical locations and regions. In the current study, the prevalence of UTI was 54.1%, with Gram-positive bacteria being more prevalent at 50% than Gram-negative (49%) and Yeast at (1%). This prevalence is higher than that from a study by Donkor (2019) [12]in Accra, Ghana, who reported a prevalence of 10.1%. In neighboring Uganda and Tanzania, a prevalence of 32.2% and 28%, respectively, have been reported, which considerably varies from the 54.1% recorded in the current study [13][7].

Furthermore, [6]reported a prevalence of 15.7% in a cross-sectional study conducted among pregnant women in a maternity hospital in Kenya. In contrast, UTI prevalence in the above African studies significantly varies from the 11% overall prevalence in the United States [14]. The variation in urinary tract infections across regions may be attributed to variations in sanitation standards, urine collection procedure and sample, UTI history, patients' age, and sex composition across the populations. Moreover, the variation in prevalence may result from differences in patient and test inclusion criteria. For instance, the present study recruited patients who only presented with UTI-like symptoms. Therefore, their urine samples were cultured regardless of their nitrates and leukocyte esterases positivity rate. On the other hand, in the study by [13], the recruited patients who presented with UTI -like symptoms but they had to cleanse the urethral area with castile soap towelette, reducing skin contamination chances.

In the present study, Gram-positive uropathogens were more prevalent (50%) than Gram-negative uropathogens (49%). This contrasts with previous studies documenting a lower prevalence of Gram-positive bacterial isolates at 21% and 12%, respectively[6] [15]. The predominance of Gram-positive bacteria could imply changing patterns of uropathogens. Other possibilities could be contamination from the skin during urine collection. Furthermore, the recovery of *Staphylococcus* species as the most dominant pathogen (34%) was different in other studies with *E.coli* as the main uropathogen. For example, in a study conducted in Kenya [15] the prevalence of *Staphylococcus* species was 21% and that of E.*coli* 38.5%, while another study conducted at Pumwani Hospital[6] had a prevalence of 15.1 % and E.*coli* at 44.5%. Also, a study conducted in Pakistan resulted in a *Staphylococcus* prevalence of 30.6% [16] . Additionally, *E.coli* was the second predominant uropathogen (26%), and the most prevalent Gram-negative bacteria, followed by *Klebsiella* species (9%) and *Proteus* species (7%) which is in agreement with a study carried out in Turkey[4] that had *E.coli* as the most frequently isolated urinary pathogen (63.7%), followed by *K. pneumoniae* (18.7%). The recovery of *Pseudomonas*(0.7%) and *Acinetobacter*(1.3%), besides *E.coli* and *Klebsiella*, represents the most resistant bacterial populations to commonly used antibiotics, including carbapenems.

Antimicrobial resistance in these uropathogens may have had a significant implication in managing urinary tract infections. However, the present study shows a high prevalence of uropathogens with high resistance toward commonly UTI antibiotics, such as Trimethoprim(64%), Sulfamethoxazole(57%), and Nalidixic Acid (57%), which corroborates previous studies[6] [17]. Anecdotal data shows that these are the commonly prescribed antibiotics at most outpatient health facilities and are easily available over the counter at chemists and pharmacies . The study found Nitrofurantoin, Amoxicillin Clavulanic Acid, with the trade name Augmentin, and Cefepime as the better choice across all the study sites; this could be

attributed to the fact that these drugs are not the first choice of treatment. The Gram-negative bacteria exhibited more resistance to the commonly used UTI drugs than the Gram-positive bacteria, which was in agreement with a recently published study in Kenya that had the same resistant trend in uropathogens isolated from Pregnant women[6]. Resistance to ciprofloxacin ranged from 12 to 67%. This trend must be closely watched since fluoroquinolones are superior to TMP/SMX for empirical therapy due to the relatively high prevalence of TMP/SMX resistance among uropathogens causing pyelonephritis [18][19]. Additionally, *Pseudomonas* and *Acinetobacter* revealed resistance towards Nitrofurantoin at 38% and 25%, respectively. This is worrying as Nitrofurantoin appears to be an ideal alternative to TMP-SMX and fluoroquinolones for empirical treatment of uncomplicated UTIs, especially given the current prevalence of antibiotic resistance among community uropathogens [20].

Additionally, variation in resistance across recruitment sites was significant. This could have been contributed by self-medication practices where the community members buy the drugs that are currently available in the chemists around. Self-medicating individuals also predominantly use the same affordable antibiotics. Different areas have different supply of antibiotics hence the variation in resistance. Elsewhere, The high rate of resistance of uropathogens to commonly used antibiotics and the emergence of *Staphylococcus aureus* as a significant causative agent could indicate a problem at the community or facility level due to wrong prescription, over-prescription, or poor adherence. This highlights the need for continuous local surveillance of susceptibility patterns of uropathogens so that a guide for empirical antibiotic prescription can be updated.

Conclusion

The study documents a high prevalence of UTIs and Gram-positive bacteria as the most dominant uropathogens implying changes in uropathogens patterns. The possible consequence of this could be a wrong antibiotics prescription since the Gram-negative bacteria have previously been prevalent. High resistance rates towards Quinolones, Sulfamethoxazole, and Trimethoprim were reported, which are the commonly used drugs as they are cheap to buy and readily available. These findings, therefore, indicate the need to amend the current empirical treatment options to reflect the results of this study. The study also highlights the need for the identification of the causative agent of UTI, even though not all hospitals have the capacity to carry out the cultures. Therefore, annual surveillance of the circulating UTI causative agents should be adopted to update the guidelines for antibiotics empirical therapy accordingly.

Funding information

The study is a subset of the large HATUA (Holistic Approach Towards Unraveling Antibacterial Resistance) consortium funded by the U.K. Medical Research Council (MR/S004785/1).

Conflict of interests

The authors declare that there are no conflicts of interest

Authors contribution

Susan Kiiru led the antibiotic susceptibility testing team and has drafted this manuscript. In addition, John Maina and Japhet Katana were crucial components of the study's methodology formulation and actualization. Dr. John Mwaniki reviewed and edited the initial drafts of this paper. Dr. John Kiiru is part of the team that conceptualized the study and overall supervisor of the HATUA Kenyan Chapter. He was the principal investigator and the one who received the funding.

Acknowledgments

We are indebted to the Medical Research Council U.K. for providing financial support to the study. We also unduly acknowledge the study collaborators, St. Andrews University, Scotland, Makerere University -in Uganda, and the Catholic University of Health and Allied Sciences in Mwanza. We also appreciate the health facilities that allowed us to conduct our study on their premises. Finally, our heart goes to the participants, whom the study couldn't have been possible without them.

References

[1] Lee DS, Lee S-J, Choe H-S, Giacobbe DR. Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance 2018. https://doi.org/10.1155/2018/7656752.

[2] Walters EM, D'Auria J, Jackson C, Walsh-Kelly C, Park D, Willis ZI. An Ambulatory Antimicrobial Stewardship Initiative to Improve Diagnosis and Treatment of Urinary Tract Infections in Children. The Joint Commission Journal on Quality and Patient Safety 2019;45:829–37. https://doi.org/10.1016/J.JCJQ.2019.08.004.

[3] Emiru T, Beyene G, Tsegaye W, Melaku S. Associated risk factors of urinary tract infection among pregnant women at Felege Hiwot Referral Hospital, Bahir Dar, North West Ethiopia. BMC Res Notes 2013;6. https://doi.org/10.1186/1756-0500-6-292.

[4] Erdem I, Kara Ali R, Ardic E, Elbasan Omar S, Mutlu R, Topkaya A. Community-acquired lower urinary tract infections: Etiology, antimicrobial resistance, and treatment results in female patients. J Glob Infect Dis 2018;10:129–32. https://doi.org/10.4103/jgid.jgid_86_17.

[5] Dash M, Padhi S, Mohanty I, Panda P, Parida B. Antimicrobial resistance in pathogens causing urinary tract infections in a rural community of Odisha, India. J Family Community Med 2013;20:20–6. https://doi.org/10.4103/2230-8229.108180.

[6] Onyango HA, Ngugi C, Maina J, Kiiru J. Urinary Tract Infection among Pregnant Women at Pumwani Maternity Hospital, Nairobi, Kenya: Bacterial Etiologic Agents, Antimicrobial Susceptibility Profiles and Associated Risk Factors. Adv Microbiol 2018;08:175–87. https://doi.org/10.4236/aim.2018.83012.

[7] Kaduma J, Seni J, Chuma C, Kirita R, Mujuni F, Mushi MF, et al. Urinary Tract Infections and Preeclampsia among Pregnant Women Attending Two Hospitals in Mwanza City, Tanzania: A 1:2 Matched Case-Control Study 2019. https://doi.org/10.1155/2019/3937812.

[8] Shiralizadeh S, Taghizadeh S, Asgharzadeh M, Shokouhi B, Gholizadeh P, Rahbar M, et al. Urinary tract infections: raising problem in developing countries. Undefined 2018;29:159–65. https://doi.org/10.1097/MRM.0000000000000144.

[9] Masika WG, Prudhomme O'meara W, Holland TL, Armstrong J. Contribution of urinary tract infection to the burden of febrile illnesses in young children in rural Kenya 2017. https://doi.org/10.1371/journal.pone.0174199.

[10] Bono MJ, Leslie SW, Reygaert WC. Urinary Tract Infection. StatPearls 2022.

[11] Sweeney MT, Lubbers B v, Schwarz S, Watts JL. Applying definitions for multidrug resistance, extensive drug resistance and pandrug resistance to clinically significant livestock and companion animal bacterial pathogens n.d. https://doi.org/10.1093/jac/dky043.

[12] Donkor ES, Horlortu PZ, Dayie NT, Obeng-Nkrumah N, Labi A-K. Community acquired urinary tract infections among adults in Accra, Ghana 2019. https://doi.org/10.2147/IDR.S204880.

[13] Odoki M, Aliero AA, Tibyangye J, Maniga JN, Wampande E, Kato CD, et al. Prevalence of Bacterial Urinary Tract Infections and Associated Factors among Patients Attending Hospitals in Bushenyi District, Uganda 2019. https://doi.org/10.1155/2019/4246780.

[14] Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol 2018;219:40–51. https://doi.org/10.1016/J.AJOG.2017.12.231.

[15] Wanja F, Ngugi C, Omwenga E, Maina J, Kiiru J, Wanja F, et al. Urinary Tract Infection among Adults Seeking Medicare at Kiambu Level 5 Hospital, Kenya: Prevalence, Diversity, Antimicrobial Susceptibility Profiles and Possible Risk Factors. Adv Microbiol 2021;11:360–83. https://doi.org/10.4236/AIM.2021.118028.

[16] Hussain T, Moqadasi M, Malik S, Salman Zahid A, Nazary K, Khosa SM, et al. Medicine, Army Medical College Rawalpindi, Rawalpindi, PAK 4. Internal Medicine, Allama Iqbal Memorial Teaching Hospital, Lahore, PAK 5. Internal Medicine, Kabul University of Medical Science, Kabul, AFG 6. Pathologist, IND 11. Neurological Surgery, Ali Abad Teaching Hospital. Jinnah Medical 2021. https://doi.org/10.7759/cureus.17527.

[17] Haque R, Akter ML, Salam MA. Prevalence and susceptibility of uropathogens: A recent report from a teaching hospital in Bangladesh. BMC Res Notes 2015;8:1–5. https://doi.org/10.1186/S13104-015-1408-1/TABLES/3.

[18] Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/19734602/ (accessed October 21, 2022).

[19] Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003;22:65–72. https://doi.org/10.1016/S0924-8579(03)00238-3.

[20] Mckinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc 2011;86:480–8. https://doi.org/10.4065/MCP.2010.0800.


UTI
St. Mary Mukuru Missionary hospital
Ruiru family clinic
Nanyuki county referral
Mbagathi hospital
Makueni Level 5
Kiambu County hospital
Kenyatta National Hospital
CMR
8.40
0.40
17.70
1.80
14.00
6.70
4.30
0.90
Recruitment Site
0.00
5.00
10.00
15.00
20.00
% UTI Prevalence

Figure


Yeast
Streptococcus
Staphylococcus
Serratia
Pseudomonas
Proteus
ND
Klebsiella
Enterococcus
E. coli
Bacillus
Acinetobacter
1(10))
0.3(3)
34.2(351)
0.7(8)
0.7(8)
7.8(79)
6.8(70)
9.4(97)
9.9(102)
26.1(268)
1.8(18)
1.3(13)
Bactreia identification
0
5
10
15
20
25
30
35
40
% proportion

Figure


PERCENTAGE
70
60
50
40
30
20
10
0
16(151)
5(53)
9(76)
8(94)
9(91)
11(109)
10(36)
4(36)
31(153)
11(55)
14(144)
25(123)
57(576)
27(272)
57(576)
64(646)
0
9(91)
23(112)
0
10(100)
35(354)
0
AMP
AMC
CXM
CAZ
CRO
CTX
FOX
CFM
ATM
AMK
GEN
RIF
NAL
CIP
SMX
TMP
FOS
NIT
LNZ
VAN
CHL
TCY
FUS
ANTIBIOTICS

Figure